Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06490055 · ClinicalTrials.gov registry record
Predicting the Efficacy in Advanced Gastric Cancer.
A clinical trial, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- 162
- Enrollment target
NCT06490055: Completed study, sponsored by City of Hope Medical Center.
NCT06490055 is a clinical trial that has completed, run by City of Hope Medical Center. The registered enrollment target is 162 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06490055 has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- 162 participants
- Enrollment target
Study Summary
With advances in chemotherapy for gastric cancer, it is important to identify patients who will respond effectively to specific therapies. This longitudinal study aimed to establish a liquid-biopsy assay that can predict response to ramucirumab plus paclitaxel therapy in patients with advanced gastric cancer.
Primary Outcome
Follows by response valuation criteria in solid tumors (RECIST) evaluation. Partial response (PR) and Stable disease (SD) are defined as treatment effective, while Progressive disease (PD) is defined as no treatment effective.
Interventions
- DRUG Paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 162 participants |
| Start Date | 2018-10-01 |
| Est. Completion | 2025-07-01 |
What the finished NCT06490055 record still lists
NCT06490055 is an observational study that tracks outcomes without assigning an intervention. The registered 162 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Paclitaxel is the first listed.
NCT06490055 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06490055 about?
NCT06490055 is a clinical study titled "Predicting the Efficacy in Advanced Gastric Cancer.". With advances in chemotherapy for gastric cancer, it is important to identify patients who will respond effectively to specific therapies. This longitudinal study aimed to establish a liquid-biopsy assay that can predict response to ramucirumab plus paclitaxel therapy in patients with advanced gastr...
What is the current status of trial NCT06490055?
This trial is currently completed. The enrollment target is 162 participants. The study started on 2018-10-01. Estimated completion is 2025-07-01.
What interventions are being tested in trial NCT06490055?
The interventions under investigation include: Paclitaxel (DRUG).
Who is sponsoring clinical trial NCT06490055?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02347111 · 162 participants · Phase 4
Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation
- NCT02610426 · 162 participants
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer
- NCT05040711 · 162 participants · NA
mHealth Mindfulness With Patients With Serious Illness and Their Caregivers
- NCT05514717 · 162 participants · Phase 1
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI